RVP

Drug Catalog - Product Detail

FUROSEMIDE INJ SOL 10MG/ML 2ML X 25

NDC Mfr Size Str Form
00409-6102-02 HOSPIRA 2 10MG/ML SOLUTION
Product Image
Generic Name
Substance Name
Product Type
Route
Application Number
Description
DESCRIPTION Furosemide is a diuretic which is an anthranilic acid derivative, chemically identified as 4‑chloro- N -furfuryl-5-sulfamoylanthranilic acid. Furosemide is a white to off-white odorless crystalline powder. It is practically insoluble in water, sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids. It has the following structural formula: Molecular formula: C 12 H 11 Cl N 2 O 5 S Molecular weight: 330.75 Furosemide Injection, USP is a sterile solution intended for intramuscular or intravenous administration. Each mL contains furosemide 10 mg and sodium chloride sufficient to render solution isotonic in water for injection. Contains sodium hydroxide and may contain hydrochloric acid for pH adjustment. pH 9.0 (8.0 to 9.3). The plastic syringe is molded from a specially formulated polypropylene. Water permeates from inside the container at an extremely slow rate which will have an insignificant effect on solution concentration over the expected shelf life. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the syringe material. Contains no preservative.
How Supplied
HOW SUPPLIED Furosemide Injection, USP 10 mg/mL is supplied as follows: NDC No. Container Size 0409-1639-10 Ansyr™ Plastic Syringe 10 mL 0409-9631-04 Ansyr™ Plastic Syringe 4 mL 0409-6102-02 Amber Fliptop Vial 2 mL 0409-6102-04 Amber Fliptop Vial 4 mL 0409-6102-10 Amber Fliptop Vial 10 mL Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Do not use if solution is discolored or contains particulate. Protect from light. Do not remove from carton until ready for use. Discard unused portion. Revised: 03/2012 EN-3018 Hospira, Inc., Lake Forest, IL 60045 USA
Indications & Usage
INDICATIONS AND USAGE Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. Edema Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Furosemide is indicated as adjunctive therapy in acute pulmonary edema. The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide is indicated by the intravenous or intramuscular route. Parenteral use should be replaced with oral furosemide as soon as practical.
Dosage and Administration
DOSAGE AND ADMINISTRATION Adults Parenteral therapy with Furosemide Injection, USP should be used only in patients unable to take oral medication or in emergency situations and should be replaced with oral therapy as soon as practical. Edema The usual initial dose of furosemide is 20 to 40 mg given as a single dose injected intramuscularly or intravenously. The intravenous dose should be given slowly (1 to 2 minutes). Ordinarily a prompt diuresis ensues. If needed, another dose may be administered in the same manner 2 hours later or the dose may be increased. The dose may be raised by 20 mg and given not sooner than 2 hours after the previous dose until the desired diuretic effect has been obtained. This individually determined single dose should then be given once or twice daily. Therapy should be individualized according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response. Close medical supervision is necessary. When furosemide is given for prolonged periods, careful clinical observation and laboratory monitoring are particularly advisable. (See PRECAUTIONS: Laboratory Tests .) If the physician elects to use high dose parenteral therapy, add the Furosemide Injection to either Sodium Chloride Injection, USP, Lactated Ringer’s Injection, USP, or Dextrose (5%) Injection, USP after pH has been adjusted to above 5.5, and administer as a controlled intravenous infusion at a rate not greater than 4 mg/min. Furosemide Injection is a buffered alkaline solution with a pH of about 9 and drug may precipitate at pH values below 7. Care must be taken to ensure that the pH of the prepared infusion solution is in the weakly alkaline to neutral range. Acid solutions, including other parenteral medications (e.g., labetalol, ciprofloxacin, amrinone, milrinone) must not be administered concurrently in the same infusion because they may cause precipitation of the furosemide. In addition, furosemide injection should not be added to a running intravenous line containing any of these acidic products. Acute Pulmonary Edema The usual initial dose of furosemide is 40 mg injected slowly intravenously (over 1 to 2 minutes). If a satisfactory response does not occur within 1 hour, the dose may be increased to 80 mg injected slowly intravenously (over 1 to 2 minutes). If necessary, additional therapy (e.g., digitalis, oxygen) may be administered concomitantly. Geriatric patients In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range (see PRECAUTIONS: Geriatric Use ). Pediatric Patients Parenteral therapy should be used only in patients unable to take oral medication or in emergency situations and should be replaced with oral therapy as soon as practical. The usual initial dose of Furosemide (intravenously or intramuscularly) in pediatric patients is 1 mg/kg body weight and should be given slowly under close medical supervision. If the diuretic response to the initial dose is not satisfactory, dosage may be increased by 1 mg/kg not sooner than 2 hours after the previous dose, until the desired diuretic effect has been obtained. Doses greater than 6 mg/kg body weight are not recommended. Literature reports suggest that the maximum dose for premature infants should not exceed 1 mg/kg/day (see WARNINGS, Pediatric Use ). Furosemide Injection should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not use if solution is discolored. To prevent needle-stick injuries, needles should not be recapped, purposely bent, or broken by hand.